Tags Archive Navigation
icon
-
Media ReleaseNovartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
-
Media ReleaseNovartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
-
Media ReleaseNovartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
-
Media ReleaseNovartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
-
Media ReleaseNovartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
-
Media ReleaseNovartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
-
Media ReleaseNovartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
-
Media ReleaseNovartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer
-
Media ReleaseNovartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteine
-
Media ReleaseNovartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovation
-
Media ReleaseNovartis continues to grow with further core margin expansion and achieves important innovation milestones
-
Media Release
Novartis continue le fort élan des principales marques de croissance, progresse dans ses initiatives stratégiques et confirme les prévisions de l’exercice 2022 pour le Groupe
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 15
- › Next page